Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: An observational study
Clinical Reviews in Allergy and Immunology, 06/30/09
Filippini M et al. – Study shows that anti-TNFα treatment reduced disease activity and led to functional improvement in both elderly and younger patients, although the baseline difference in HAQ remained statistically significant at the end of the follow-up. The elderly patients experienced more infective events.
Methods- A comparison of the efficacy and safety of anti-TNF agents in elderly (aged ≥65 yrs) and younger pts (aged 18–65 yrs) with active RA
- 1,114 RA pts, followed-up for >6 mo, were divided into 2 cohorts on the basis of their age to evaluate 3-yr outcomes and treatment discontinuations
- Drug effectiveness was assessed by DAS28 and EULAR response, functional status (HAQ) and serological parameters (ESR) at baseline and during therapy
- Safety was evaluated on the basis of drug discontinuation rates
- At baseline, the elderly pts showed greater disease activity and loss of joint function
- During therapy, clinical and laboratory parameters improved in both groups w/o any difference between them
- Difference in HAQ remained after 36 mo of treatment
- Anti-TNFα therapy was discontinued by 42% elderly and 36.6% of younger pts because of loss of efficacy, severe adverse events or other reasons
- Number of AEs was higher in the elderly patients
Related Articles
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09
Relevance Score: 70%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09
Relevance Score: 69%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
ALO-01 (Morphine Sulfate and Naltrexone Hydrochloride) Extended-Release Capsules in the Treatment of Chronic Pain of Osteoarthritis of the Hip or Knee: Pharmacokinetics, Efficacy, and Safety
The Journal of Pain, 12/02/09
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review
Rheumatology, 12/01/09
Beyond conventional DMARDs: extending TNF-regulant therapies to the vast majority/less privileged who do need them
International Journal of Rheumatic Diseases, 11/30/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production
Arthritis Research & Therapy, 11/25/09
No evidence for association of the KLF12 gene with RA in a large UK cohort of >7,000 samples.
Annals of Rheumatic Diseases, 11/23/09
New classification of the shared epitope in rheumatoid arthritis: Impact on the production of various anti-citrullinated protein antibodies
Rheumatology, 11/20/09
Sponsor
Article Search
Sponsor


See Latest Articles


